

AML Hub continues to enhance global knowledge of acute myeloid leukemia throughout 2021

Monday 19 July, 2021

Press Release: Available for Immediate Release

The [AML Hub](#), run by [Scientific Education Support \(SES\)](#) in partnership with the [European LeukemiaNet \(ELN\)](#), has continued to promote significant developments in the treatment and research of acute myeloid leukemia (AML) throughout Quarter 2 of 2021. The AML Hub provides up-to-date, unbiased material for healthcare professionals within the AML community, worldwide.

Input from the hub's [executive steering committee](#) and [scientific advisory board](#) allows the AML Hub to gauge the latest content demands and to deliver material of the highest value. On May 25, 2021, the AML Hub held a virtual steering committee meeting, which highlighted the achievements of the AML Hub, as well as the unmet clinical needs in the AML setting and how to address them. The success of the virtual format of the meeting further emphasized the versatility and resilience of the AML Hub and its affiliates.

Speaking about the success of the hub's activity, Mia Hill, IME director at Scientific Education Support, said:

"In the second quarter of 2021, the AML Hub continued to successfully navigate the virtual climate, remotely covering the 2021 Korean Society of Hematology International Conference & 62nd Annual Meeting (ICKSH 2021), the Acute Leukemia Forum (ALF) 2021, the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, and the European Hematology Association (EHA) 2021 Virtual Congress. The AML Hub provided a combination of live and on-demand social media coverage of key sessions and conducted interviews with experts in the field of AML.

For the first time, in order to help navigate the exciting content being presented at the EHA2021 Virtual Congress, members of the AML Hub Executive Steering Committee kindly provided their insights into the [top abstracts](#) to look out for in AML. We compiled both the clinical content and the disease biology sessions in the form of a downloadable resource, including links to view the abstracts."

The hub has faced several challenges throughout 2021, and reflecting on these challenges, Mia Neve said:

"The SARS-CoV-2 pandemic has challenged healthcare services and individuals worldwide, especially patients with hematologic malignancies. The AML Hub is working hard to bring you the latest information regarding COVID-19 and its implications in the AML setting: a summary of the guidelines on [COVID-19 vaccination for hematopoietic stem cell transplant patients](#) has been published, based on expert recommendations presented during the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT).

The AML Hub owes thanks to its supporters —Roche Genentech, AbbVie, Amgen, Novartis, Bristol Myers Squibb, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Gamida Cell, and Takeda —without whom the work would not be possible. In Quarter 2, the AML Hub was delighted to welcome Syndax as a supporter and would like to extend a special thanks for their support going forward."

ENDS

For more information on the AML Hub, please visit aml-hub.com.

For media enquiries or to explore collaboration opportunities, please contact secretariat@scientificeducationsupport.com.

About acute myeloid leukemia (AML)

Leukemia is cancer of the white blood cells. Acute leukemia means that the cancer progresses quickly and aggressively, and usually requires immediate treatment.

Acute leukemia is classified according to the type of white blood cells affected. There are two main types of white blood cells:

Media:

Related Sectors:

Media & Marketing :: Medical & Pharmaceutical ::

Scan Me:



- lymphocytes—cells that fight viral infections.
- myeloid cells—cells that have a variety of functions, such as fighting bacterial infections, defending the body against parasites, and preventing the spread of tissue damage.

AML is an aggressive cancer of the myeloid cells.

About the AML Hub

The AML Hub is an open-access online resource dedicated to providing balanced, credible, and up-to-date medical education in AML. Our aim is to enhance knowledge on AML through the multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management.

The AML Hub is the solution for a time-stretched HCP to easily access impactful information that expedites learning and empowers their treatment decisions. Informed by patients, curated by world leaders and endorsed by expert societies the AML Hub supports HCPs worldwide.

The AML Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.

AML Hub supporters

Funding for our hubs are made possible through financial support from the pharmaceutical industry. ?All content is developed by SES in collaboration with an expert Steering Committee. ?All content is independent, and the educational supporters are allowed no influence on the content.?

- Genentech
- Roche
- AbbVie
- Amgen
- Novartis
- Bristol Myers Squibb
- Syndax
- Janssen Oncology
- Jazz Pharmaceuticals
- Gamida Cell
- Takeda

If you are interested in becoming an AML supporter, please contact secretariat@scientificeducationsupport.com

About Scientific Education Support (SES)

SES is a medical education company with projects such as community physician education through our therapy hubs, community awareness and education through our 'KNOW' education initiatives, and academic researcher education through Entrepreneurs in Clinical Academia (ECA) programs.

Scientific Education Support already has a portfolio of successful websites supporting the advancement of medical education in the field of hemato-oncology, which includes the [Lymphoma Hub](#), [AML Hub](#), [Multiple Myeloma Hub](#), [GvHD Hub](#), [MPN Hub](#), and [MDS Hub](#).

About the European LeukemiaNet

The European LeukemiaNet cooperates with 220 participating centers in 44 countries, with more than 1,000 researchers and clinicians. The objective is to integrate about 120 leading leukemia trial groups (CML, AML, ALL, CLL, MDS, MPN), their interdisciplinary partner groups (diagnostics, treatment research, registry, guidelines), industry, and SME s across Europe to form a network promoting cooperative research for curing leukemia.

Company Contact:

Scientific Education Support

E. [Abbie.Gunn@scientificeducationsupport...](mailto:Abbie.Gunn@scientificeducationsupport.co.uk)

W. [https://www.scientificeducationsuppor...](https://www.scientificeducationsupport.co.uk)

[View Online](#)

Additional Assets:

<https://aml-hub.com/>

Newsroom: Visit our Newsroom for all the latest stories:

<https://www.scientific-education-support.pressat.co.uk>